Oudkerk, Matthijs, Liu, ShiYuan, Heuvelmans, Marjolein A, Walter, Joan E and Field, John K 
ORCID: 0000-0003-3951-6365
(2021)
Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives.
Nature Reviews Clinical Oncology, 18 (3).
pp. 135-151.
|
Text
Oudkerk et al - Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives— evidence, pitfalls and future perspectives Word Version.pdf - Author Accepted Manuscript Download (1MB) | Preview |
Abstract
In the past decade, the introduction of molecularly targeted agents and immune-checkpoint inhibitors has led to improved survival outcomes for patients with advanced-stage lung cancer; however, this disease remains the leading cause of cancer-related mortality worldwide. Two large randomized controlled trials of low-dose CT (LDCT)-based lung cancer screening in high-risk populations - the US National Lung Screening Trial (NLST) and NELSON - have provided evidence of a statistically significant mortality reduction in patients. LDCT-based screening programmes for individuals at a high risk of lung cancer have already been implemented in the USA. Furthermore, implementation programmes are currently underway in the UK following the success of the UK Lung Cancer Screening (UKLS) trial, which included the Liverpool Health Lung Project, Manchester Lung Health Check, the Lung Screen Uptake Trial, the West London Lung Cancer Screening pilot and the Yorkshire Lung Screening trial. In this Review, we focus on the current evidence on LDCT-based lung cancer screening and discuss the clinical developments in high-risk populations worldwide; additionally, we address aspects such as cost-effectiveness. We present a framework to define the scope of future implementation research on lung cancer screening programmes referred to as Screening Planning and Implementation RAtionale for Lung cancer (SPIRAL).
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Humans, Lung Neoplasms, Tomography, X-Ray Computed, Risk Factors, Dose-Response Relationship, Drug, Cost-Benefit Analysis, Randomized Controlled Trials as Topic, Early Detection of Cancer, Immune Checkpoint Inhibitors |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 19 Oct 2020 09:06 |
| Last Modified: | 18 Jan 2023 23:27 |
| DOI: | 10.1038/s41571-020-00432-6 |
| Open Access URL: | https://pubmed.ncbi.nlm.nih.gov/33046839/ |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3104536 |
Dimensions
Dimensions
